Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (46)

I-004Arkadiusz Adamiszak

Do critically ill patients undergoing continuous renal replacement therapy require levofloxacin dosage adjustments? Levofloxacin PopPK model and dosage simulations based on retrospective data and developed using open-source R packages.

Wednesday 10:30-12:00

I-049Jose Miguel Calderin Miranda

Semi-mechanistic population pharmacokinetic modelling of the novel antituberculosis drug TBAJ-876 and its metabolite M3 in healthy volunteers

Wednesday 10:30-12:00

I-062Yi-han Chien

Modelling framework to evaluate anti-viral PROTACs

Wednesday 10:30-12:00

I-066Wendy Chu

Pharmacokinetics of the antimalarial drug pyronaridine: impact of pregnancy, malaria infection and HIV co-infection

Wednesday 10:30-12:00

I-077Salvatore D'Agate

A model-based approach for the characterisation of anti-tubercular effects of BPaL combination therapy in an in vitro time-kill assay

Wednesday 10:30-12:00

I-078Harel Dahari

Beyond the RSE: Improving accuracy of in-host population modeling

Wednesday 10:30-12:00

I-091Marie-Laure Delporte

A pharmacokinetics–time to alleviation of symptoms model to support extrapolation of baloxavir marboxil efficacy in pediatric patients with influenza

Wednesday 10:30-12:00

I-107Khanh Linh Duong

Population Pharmacokinetic Model of Darunavir and Ritonavir in Pregnant and Postpartum Women with Human Immunodeficiency Virus Infection

Wednesday 10:30-12:00

I-109Aspire Editor

Population Pharmacokinetic Analysis of Lenacapavir in People Who Want or Need Pre-Exposure Prophylaxis

Wednesday 10:30-12:00

I-114Ibrahim El-haffaf

Joint model for piperacillin and meropenem: assessing the impact of a joint pharmacokinetic modeling approach on covariate inclusion and probability of target attainment

Wednesday 10:30-12:00

II-018Asina Gijasi

Predicting later-phase clinical trial efficacy in tuberculosis through back-translational modeling of rifapentine-containing regimens

Wednesday 15:30-17:00

II-021Nele Goeyvaerts

Viral kinetic modeling of mosnodenvir prophylaxis against DENV-3 in a controlled human infection model

Wednesday 15:30-17:00

II-029Nicolas Grégoire

Simulation-based prediction of pharmacokinetic/pharmacodynamic (PK/PD) index for Linezolid to treat cerebral infections in critically ill patients

Wednesday 15:30-17:00

II-031Meng Gu

Collateral sensitivity-driven dosing strategies in bacteriophage-antibiotic combination therapy: a mechanism-based approach

Wednesday 15:30-17:00

II-039Miriam Stephanie Rosemarie Happ

The impact of bacterial growth kinetics on predicted antibiotic efficacy under different pharmacodynamic model assumptions: An in vivo case example

Wednesday 15:30-17:00

II-042Bibi Hellinghus

Free IL-6 Following Treatment with Ziltivekimab in a Population with Moderate-to-Severe Chronic Kidney Disease

Wednesday 15:30-17:00

II-043Rasmus Henninger

Target site pharmacokinetics-pharmacodynamics of DNDI-6148 in a murine Leishmania major skin infection model: integrating parasite bioluminescent imaging and lesion dynamics

Wednesday 15:30-17:00

II-064Evangelos Karakitsios

Extrapolation of Lung Pharmacokinetics from Preclinical Species and Implications for Dose Selection in Humans: the role of physiologically based pharmacokinetic modeling in the development of antitubercular drugs.

Wednesday 15:30-17:00

II-069Sonoko Kawakatsu

Population Pharmacokinetic Analysis of Tenofovir Alafenamide (TAF) and Tenofovir (TFV) in Adolescents and Children with HIV-1

Wednesday 15:30-17:00

II-073Allan Kengo

Pharmacogenetics-guided isoniazid dosing in individuals with tuberculosis and HIV

Wednesday 15:30-17:00

II-101Albin Leding

Early phase 2a dose recommendation for 2nd generation diarylquinoline TBAJ-587

Wednesday 15:30-17:00

II-105Annabelle Lemenuel-diot

A novel mechanistic viral dynamics modeling (MVDM) framework to characterize the effect of combination therapies in chronic hepatitis B and evaluate the influence of individual characteristics in the Piranga phase 2 platform study

Wednesday 15:30-17:00

II-106Cristhyne Leon

Expansion of a mechanistic model of recurrent respiratory infections in children to the elderly and chronic obstructive pulmonary disease populations

Wednesday 15:30-17:00

II-114Yu-Jou Lin

An interactive pharmacokinetic, pharmacodynamic, and long-term outcome model framework to evaluate bedaquiline dose modifications in adults with tuberculosis

Wednesday 15:30-17:00

III-006Xuanlin Liu

Mechanistic viral dynamic modeling of in vitro cytomegalovirus infection based on the amount of viral DNA and viral titer

Thursday 9:50-11:45

III-038Laurynas Mockeliunas

Repeated-time-to-event modelling predicting respiratory tract infections during the COVID-19 pandemic

Thursday 9:50-11:45

III-049Bonginkosi Ndzamba

Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV

Thursday 9:50-11:45

III-051Thi Minh Nguyet Nguyen

Informativeness of different in vitro Mycobacterium tuberculosis culture phases in time-kill assay for pharmacokinetic-pharmacodynamic translation

Thursday 9:50-11:45

III-056Ivan Nicholas Nkuhairwe

Population pharmacokinetics of amikacin in Indian patients with multi-drug-resistant tuberculosis

Thursday 9:50-11:45

III-083Yuan Pétermann

Characterization of rifampicin pharmacokinetics in Tanzanian and South African populations

Thursday 9:50-11:45

III-086Anh Duc Pham

Mechanism-based model of the innate immune response in bacteraemia to assess antibiotic PK/PD targets in immune competent and immune compromised hosts

Thursday 9:50-11:45

III-089Veshni Pillay-Fuentes Lorente

Population pharmacokinetics of colistimethate sodium following intravenous administration in critically ill South African adults

Thursday 9:50-11:45

III-090Émilie Pilote

Population Pharmacokinetics of Dolutegravir: A Narrative Review

Thursday 9:50-11:45

IV-011Sharon Sawe

Population pharmacokinetic modelling as a screening tool to expedite evidence for hard-to-study populations: a case study of atazanavir/ritonavir in people with HIV.

Thursday 15:00-16:45

IV-035Chrisoula Tahtsidou

Population pharmacokinetics of orally administered letermovir in real world allogeneic hematopoietic cell transplantation recipients

Thursday 15:00-16:45

IV-041Charlotte M Thomas

Pharmacokinetics of Flucytosine in HIV-positive adults with cryptococcal meningitis adults in Africa

Thursday 15:00-16:45

IV-067Wisse van Os

A PK/PD workflow to support the selection of empirical antibiotic combination therapies: application to neonatal sepsis

Thursday 15:00-16:45

IV-071Alberto Vegas Rodriguez

INTEGRATED POPULATION PKPD MODELLING OF VIRAL DYNAMICS AND HOST IMMUNE RESPONSE IN HIV PATIENTS UNDERGOING ANTIRETROVIRAL MONOTHERAPY

Thursday 15:00-16:45

IV-072Peter Velickovic

Do differences in pharmacokinetics overcome resemblances in immune system characteristics in cynomolgus macaques for the evaluation of antitubercular drugs?

Thursday 15:00-16:45

IV-074Umberto Villani

In vitro-in silico characterisation of host-directed therapeutics combined with antimicrobials in tuberculosis

Thursday 15:00-16:45

IV-080Chenyu Wang

Evaluating the Relationship Between Experimental EC50 Values and Mechanism-Based Model Parameters in Viral Dynamics models

Thursday 15:00-16:45

IV-081Qianwen Wang

Population Pharmacokinetics Modelling of Ibrexafungerp Using Data from Healthy Volunteers

Thursday 15:00-16:45

IV-086Eva Wehrhahn

Bacterial morphology-based pharmacokinetic-pharmacodynamic models of carbapenem-exposed Gram-negative bacteria

Thursday 15:00-16:45

IV-098Aysenur Yaliniz

Population Pharmacokinetic Modeling of Amoxicillin in Penguins

Thursday 15:00-16:45

IV-101Risa Yokokawa

Mathematical modeling of immune response following mRNA- or protein-based vaccine for SARS-CoV-2

Thursday 15:00-16:45

IV-108Shengyuan Zhang

A mechanistic model describing antibody response and SARS-CoV-2 viral loads

Thursday 15:00-16:45